Covaxin can work against mutated coronavirus, confirms Bharat Biotech
The executive said Covaxin, now undergoing Phase 3 trials involving about 20,000 volunteers, balances both safety and efficacy.
Share Via Email
| A+A A- By PTI
HYDERABAD:
Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman and Managing Director of the city-based vaccine maker Krishna Ella said on Tuesday.
He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology and now undergoing phase 3 trials.
Covaxin can work against mutated coronavirus: Bharat Biotech
SECTIONS
Last Updated: Dec 29, 2020, 07:26 PM IST
Share
Synopsis
He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology and now undergoing phase 3 trials.
Agencies It will also take care of those mutations, Ella said during a virtual programme organised by CSIR-Indian Institute of Chemical Technology.
Hyderabad: Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman and Managing Directorof the city-based vaccine maker Krishna Ella said on Tuesday. He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICM
Covaxin can work against mutated coronavirus because of two hypotheses: Bharat Biotech
India
Updated: Tuesday, December 29, 2020, 19:46 [IST]
Hyderabad, Dec 29: Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman and Managing Directorof the city-based vaccine maker Krishna Ella said on Tuesday.
He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology and now undergoing phase 3 trials. It (coronavirus) is expected to have a lot of mutation and you can be rest assured this vaccine will also protect against that (mutated) virus because of two hypotheses. So you have these two components in the inactivated vaccine. It will also take care of those mutations, Ella said during a virtual programme organised by CSIR
Covaxin can protect against COVID-19 mutant: Bharat Biotech
Bharat Biotech MD also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with ICMR and the National Institute of Virology and now undergoing phase 3 trials
PTI | December 29, 2020 | Updated 20:55 IST
The executive said Covaxin, now undergoing Phase 3 trials involving about 20,000 volunteers, balances both safety and efficacy
Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman and Managing Directorof the city-based vaccine maker Krishna Ella said on Tuesday. He also said the company has approached regulatory authorities seeking approval for an emergency license to use the vaccine, developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology and now undergoing phase 3 trials.
IICT scientist delivers keynote address on globalisation and Atmanirbhar Bharat
Science & technology has a significant role to play in achieving the aim of self-reliant India with the Central government, too, according it priority. CSIR scientists, in particular, have been playing a key role not only in combating COVID-19 but also in space research, development of indelible ink, drugs, pheromone application technology and White Revolution, said M. Chandrasekharam, senior principal scientist, CSIR-Indian Institute of Chemical Technology (IICT) on Tuesday.
Delivering the keynote address of the webinar on ‘Globalisation-self reliant India - The need, the transformation and the way forward’ organised by the Press Information Bureau and the Regional Outreach Bureau of the Ministry of Information & Broadcasting, he said scientists and researchers are playing their role in making India self-reliant in all fields.